Condition
Primary Liver Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06342414Recruiting
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT03397654Phase 1CompletedPrimary
Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
NCT02014025Not ApplicableCompletedPrimary
Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC
Showing all 3 trials